marked.bio

HER3 ADC · ADC

SHR-A2009

3 active trials, targeting HER3. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
EGFR exon 19 deletion / L858R 3 3 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of SHR-A2009.

  1. Jiangsu Hengrui 2
  2. Hansoh Pharma 1

Trials

3 of 3 trials shown

  1. A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

    Active, not recruiting Phase 3 Jiangsu Hengrui Started 2025Primary completion 2032-11 NCT07183189

    SHR-A2009aumolertinib

    …lly confirmed locally advanced, metastatic, or recurrent non-small cell lung cancer, with EGFR mutations confirmed by tissue or blood specimens.

    EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer

  2. A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

    Active, not recruiting Phase 3 Jiangsu Hengrui Started 2024Primary completion 2026-12 NCT06671379

    SHR-A2009platinum-based dual-agent chemotherapy

    A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

    EGFR exon 19 deletion / L858RNon-small Cell Lung Cancer

  3. A Phase Ib Study of HS-10504 Combined Therapy in NSCLC

    Not yet recruiting Phase 1 Hansoh Pharma Started 2026Primary completion 2027-04 NCT07414953

    HS-10504SHR-A2009HS-20122HS-20117SHR-1826SHR-A2102

    Cohort1:participants with EGFR mutation advanced stage NSCLC，disease progression on or after prior treatment；

    EGFR exon 19 deletion / L858RLung Cancer